Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cholesterol, an essential component of the brain, and its local metabolism are involved in many neurodegenerative diseases. The blood-brain barrier is impermeable to cholesterol; hence, cholesterol homeostasis in the central nervous system represents a balance between in situ biosynthesis and elimination. Cytochrome P450 46A1 (CYP46A1), a central nervous system-specific enzyme, converts cholesterol to 24-hydroxycholesterol, which can freely cross the blood-brain barrier and be degraded in the liver. By the dual action of initiating cholesterol efflux and activating the cholesterol synthesis pathway, CYP46A1 is the key enzyme that ensures brain cholesterol turnover. In humans and mouse models, CYP46A1 activity is altered in Alzheimer’s and Huntington’s diseases, spinocerebellar ataxias, glioblastoma, and autism spectrum disorders. In mouse models, modulations of CYP46A1 activity mitigate the manifestations of Alzheimer’s, Huntington’s, Nieman-Pick type C, and Machao-Joseph (spinocerebellar ataxia type 3) diseases as well as amyotrophic lateral sclerosis, epilepsy, glioblastoma, and prion infection. Animal studies revealed that the CYP46A1 activity effects are not limited to cholesterol maintenance but also involve critical cellular pathways, like gene transcription, endocytosis, misfolded protein clearance, vesicular transport, and synaptic transmission. How CYP46A1 can exert central control of such essential brain functions is a pressing question under investigation. The potential therapeutic role of CYP46A1, demonstrated in numerous models of brain disorders, is currently being evaluated in early clinical trials. This review summarizes the past 70 years of research that has led to the identification of CYP46A1 and brain cholesterol homeostasis as powerful therapeutic targets for severe pathologies of the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 1×
“Conversely, CYP46A1 inhibition could be of therapeutic value in pathological conditions that promote excessive glutamatergic excitation such as those occurring in schizophrenia, epilepsy, and hyperalgesia (Coyle, 2006; Xia et al., 2010; Sun et al., 2016b; Lu et al., 2020).”
BackgroundCholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906 · cited 3×
“In white matter, cholesterol is at an abundance in myelin sheaths (∼70% of total brain cholesterol as determined in mice) (Dietschy and Turley, 2001, 2004), which represent greatly extended and modified plasma membranes of oligodendrocytes wrapped around axons in a spiral fashion (Quarles et al.,…”
BackgroundInfluentialLütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Sidén, A., Diczfalusy, U., & Björkhem, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9799 · Cited by 682 · cited 2×
“Plasma 24HC levels were determined to markedly depend on age and be ∼5 times lower in the sixth decade of human life than in the first decade of life (Lutjohann et al., 1996). cDNAs for mouse and human cholesterol 24-hydroxylases were cloned in 1999 and demonstrated to convert cholesterol to 24HC…”
BackgroundcDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain
Lund, E. G., Guileyardo, J. M., & Russell, D. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7238 · Cited by 668
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Neurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Björkhem, I., Lütjohann, D., Diczfalusy, U., Ståhle, L., Ahlborg, G., & Wahren, J. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32188-x · Cited by 538
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421
Cited by
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Brain cell type-specific cholesterol metabolism and implications for learning and memory
Li, D., Zhang, J., & Liu, Q. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.01.002 · Cited by 163
Valencia-Olvera, A. C., Balu, D., Faulk, N., Amiridis, A., Wang, Y., Pham, C., Avila-Munoz, E., York, J. M., Thatcher, G. R. J., & LaDu, M. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01375-3 · Cited by 22
Brain Cholesterol Biosynthetic Pathway Is Altered in a Preclinical Model of Fragile X Syndrome
Parente, M., Tonini, C., Buzzelli, V., Carbone, E., Trezza, V., & Pallottini, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063408 · Cited by 11
“Indeed, CYP46A1 is a key brain-specific enzyme that converts cholesterol to 24-hydroxycholesterol (24 HC), which is able to cross the BBB and to reach the liver to be degraded [48].”
BackgroundModulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome
Audouard, E., Khefif, N., Gillet-Legrand, B., Nobilleau, F., Bouazizi, O., Stanga, S., Despres, G., Alves, S., Lamazière, A., Cartier, N., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060756 · Cited by 7
“…targets the cholesterol pathway since RTT patients and mice have shown deficits in this pathway [11–17], and as we have previously demonstrated in Alzheimer, ALS, SCA, and Huntington mouse models, the overexpression of CYP46A1 can restore or improve some symptoms present in these models [29,30,70].”
BackgroundSelf-citation
Metadata
- Authors
- Pikuleva, I. A., & Cartier, N.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-07-08
- Volume
- 13
- Pages
- 696778-696778
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W3179713897
- Cited by
- 80
- References
- 25
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications. https://app.cochat.ai/papers/10.3389/fnagi.2021.696778
- The paper
- Pikuleva, I. A., & Cartier, N. (2021). Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2021.696778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.